Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects

Jane Freedman, Mary A. Mascelli, John C. Pezzullo, Elliot S. Barnathan, Bart Frederick, Robert E. Jordan, Darrell R. Abernethy

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of the study was to establisha rebolus regimen for abciximab that restores pharmacologic glycoprotein (GP) IIb/IIIa receptor blockade within a short rime frame (up to 48 hours) after completion of an initial treatment. Methods and Results: The study was a single-center, nonrandomized, open-label dose escalation trial in healthy volunteers (n = 30). Each subject received a 0.25 mg/kg bolus and a 0.125 μg/kg per minute infusion of abciximab, followed by incremental bolus doses of the agent at 15-minute intervals up to 48 hours (10 per group) after completion of the infusion, (maximal cumulative rebolus dose of 0.25 mg/kg). Pharmacodynamic measurements (GP IIb/IIIa receptor blockade, turbidimetric and whole blood platelet aggregation with use of a rapid platelet function assay [RPFA]) were obtained at periodic intervals during and after administration of the abciximab bolus and infusion. At the time of the first rebolus, pharmacodynamic measurements were attained immediately before administration of each rebolus and 15 minutes after the last rebolus dose. In subjects who received reboluses 12 hours after infusion, a cumulative dose of 0.05 mg/kg restored >80% blockade of GP IIb/IIIa receptors and >80% inhibition of turbidimetric (5 and 20 μmol/L adenosine diphosphate) and RPFA aggregation in 10 of 10 subjects. At 24 hours after treatment, a cumulative abciximab bolus dose of 0.1 mg/kg restored >80% blockade of all 4 pharmacodynamic measurements in 10 of 10 subjects. At 48 hours after treatment, a cumulative bolus dose of 0.15 mg/kg restored >80% blockade of all 4 pharmacodynamic measurements in 10 of 10 subjects. Conclusions: A fraction of the bolus of abciximab restored pharmacologic (>80%) GP IIb/IIIa receptor blockade when readministered at various postinfusion time points. These observations suggest that in the setting where acute readministration of abciximab is required less than a full bolus dose of the agent is warranted.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalAmerican heart journal
Volume143
Issue number1
DOIs
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects'. Together they form a unique fingerprint.

  • Cite this

    Freedman, J., Mascelli, M. A., Pezzullo, J. C., Barnathan, E. S., Frederick, B., Jordan, R. E., & Abernethy, D. R. (2002). Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects. American heart journal, 143(1), 87-94. https://doi.org/10.1067/mhj.2002.119769